Skip to main content
OpenTrials
Completed

NCT Number: NCT03134339

The Effect of Nicotine Delivery Rate on Reinforcement

The dose-effect curve to estimate a threshold delivery rate for reinforcement. The project addresses the FDA Center for Tobacco Products (CTP) interest #1: Nicotine dependence threshold among youth and adults and impact of nicotine reduction on tobacco product use behavior (e.g., topography, compensation, switching, multiple use, initiation, cessation and relapse). IV nicotine, in contrast to ECs, can deliver precise, reproducible dosing, which is necessary for accurately assessing dose-response and threshold effects. The estimated threshold for reinforcement will establish a benchmark for evaluating the addictive potential of ECs and other inhaled nicotine products.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–30 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

VA Hospital

West Haven, Connecticut, 06516, United States

About this study

A placebo-controlled study that will recruit male and female nicotine dependent smokers/EC users (n=18) to complete four separate experimental sessions. Each session will include one randomly assigned infusion that will be either saline or a single dose of nicotine (1 mg per 70 kg body weight) delivered at three different infusion rates, rapid, moderate or slow (0.24, 0.048 or 0.024 mcg per kg body weight per second). A total infusion duration of 10 min will be maintained during each session by adding saline infusions of variable duration after nicotine delivery. This will be achieved by two separate infusion pumps, one for saline and one for nicotine. For example, the rapid 0.24 mcg/kg/s condition will include a 1 min infusion of nicotine followed by a 9 min infusion of saline. The subjects will be blinded to the infusion pump procedures. The rapid delivery rate, which we have used in our prior studies, induces positive subjective drug effects and suppresses symptoms of nicotine withdrawal. The moderate delivery rate,0.048 mcg/kg/s, approximates the rate of nicotine intake encountered while smoking a typical cigarette over 5 min (4). The slowest nicotine delivery rate, 0.024mcg/kg/s, was chosen to approximate the rate of nicotine intake encountered while using a newer EC (5).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female and male smokers that smoke ≥ 5 cigarettes per day for the past year
  • aged 18 to 30 years
  • urine cotinine levels > 100 ng/mL consistent with nicotine intake of an active smoker (23)
  • not seeking treatment at the time of the study for nicotine dependence
  • in good health as verified by medical history, screening examination, and screening laboratory tests
  • for women, not pregnant as determined by pregnancy screening, nor breast feeding, and using acceptable birth control methods.

Exclusion criteria

  • history of major medical or psychiatric disorders that the physician investigator deems as contraindicated for the subject to be in the study
  • regular use of psychotropic medication (antidepressants, antipsychotics, or anxiolytics)
  • current alcohol or substance dependence for any other recreational or prescription drugs other than nicotine
  • urine drug screening indicating recent illicit drugs use (with the exception of marijuana).

Treatment and study plan

Nicotine saline 0.00mcg/kg/s

Drug

saline 0.00mcg/kg/s

Other names: nicotine infusion

Nicotine 0.24 mcg/kg/s

Drug

nicotine 0.24 mcg/kg/s

Other names: nicotine infusion

Nicotine 0.048 mcg/kg/s

Drug

nicotine 0.048 mcg/kg/s

Other names: nicotine infusion

Nicotine 0.024 mcg/kg/s

Drug

nicotine 0.024 mcg/kg/s

Other names: nicotine infusion

Primary outcomes

  1. Peak Change on items of the Drug Effects Questionnaire (DEQ)

    Time frame: up to 60 minutes post infusion

    The peak change in the intensity of subjective effects as measured by the DEQ

Sponsors and collaborators

Lead sponsor

Yale University

Other

Registry information

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Apr 28, 2017
Registry last updated
Oct 22, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.